Article Text

Download PDFPDF
Case report
Comorbidity between progressive familial intrahepatic cholestasis and atopic dermatitis in a 19-month-old child
  1. Ilenia Panasiti1,
  2. Silvana Briuglia2,
  3. Stefano Costa3 and
  4. Lucia Caminiti1
  1. 1 Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy
  2. 2 Department of Biomedical Sciences, Medical Genetics, University of Messina, Messina, Italy
  3. 3 Department of Pediatrics, Pediatric Gastroenterology and Cystic Fibrosis Unit, University of Messina, Messina, Italy
  1. Correspondence to Dr Ilenia Panasiti; ileniapanasiti89{at}gmail.com

Abstract

Atopic dermatitis (AD) is the most common chronic skin disease in children, with an increasing prevalence in the past three decades. Adequate treatment is prescribed for individual patient based on symptoms and disease severity. However, further underlying diagnosis should be researched when therapeutic strategies for symptoms fail and skin lesions and pruritus persist. We reported herein the case of a 19-month-old infant with a history of AD unresponsive to treatment due to the type 2 progressive familial intrahepatic cholestasis (PFIC). A new homozygous mutation of the ABCB11 gene was found. The severe pruritus, the early onset jaundice, poor growth and raised transaminase levels with normal gamma glutamyl transpeptidase have led to the suspicion of PFIC. The presence of severe AD and intrahepatic chronic cholestasis, both pruritus associated, could delay a proper diagnosis. To our knowledge, for the first time, a case of comorbidity between type 2 PFIC and AD-like disease had been described.

  • liver disease
  • paediatrics
  • bilirubin disorders
  • congenital disorders
  • failure to thrive
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors IP wrote the manuscript with support from LC, SB and SC. IP, LC and SC follow the patient periodically. LC and SB supervised the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.